Preview

Рецепт

Расширенный поиск

Сахарный диабет, дисгликемия и COVID-19: новое в коррекции и профилактике осложнений

https://doi.org/10.34883/PI.2020.2.2.042

Полный текст:

Аннотация

Качество метаболической компенсации диабета определяет не только скорость прогрессирования его осложнений, но и состояние противовирусного и противомикробного иммунитета. Обсуждается реализация международных руководств по лечению диабета во время острых респираторных инфекций и COVID-19. Международные рекомендации по коррекции внутрибольничной дисгликемии, собственный опыт авторов указывают на возможность индивидуализации гликемических параметров при внутривенном введении короткого или ультракороткого инсулина в отделении интенсивной терапии и реанимации (ОИТР) на основе оценки метаболического статуса пациентов и ожидаемых перспектив. Выживаемость выше при более жестких целевых значениях гликемии при минимизации гипогликемий. Можно ли перенести этот клинический опыт на ситуацию с внутрибольничной гипергликемией у пациентов ОИТР с COVID-19, покажут в дальнейшем результаты анализа эффективности различных терапевтических подходов, включая применение ряда лекарственных средств.

Об авторах

Л. И. Данилова
Белорусская медицинская академия последипломного образования
Беларусь


М. Л. Лущик
Белорусская медицинская академия последипломного образования
Беларусь


О. Н. Исачкина
10-я городская клиническая больница
Беларусь


В. В. Валуевич
Белорусская медицинская академия последипломного образования
Беларусь


Список литературы

1. IDF (2019) International Diabetes Federation Diabetes Atlas 9th edition, Brussels. https://diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf

2. Harding J.L. Benoit S.R., Gregg E.W., Pavkov M.E., Perreault L. (2020) Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000–2015. Diabetes Care, vol. 43, pp. 106–116.

3. Fadini G.P., Morieri M.L., Longato E., Avogaro A. (2020) Prevalence and impact of diabetes among people infected with SARS‐CoV‐2. Endocrinological Investigation. doi:10.1007/s40618-020-01236-2

4. Wang B., Li R., Lu Z., Huang Y. (2020) Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Agin, vol. 12, no 7, pp. 6049–6057.

5. Bornstein S.R. Rubino F., Khunti K. (2020). Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet, (electronic journal) doi.org/10.1016/S2213-8587(20)30152-2/

6. Harding J.L. Benoit S.R., Gregg E.W., Pavkov M.E., Perreault L. (2020) Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000-2015. Diabetes Care, vol 43, pp. 106–116.

7. IDF (2020) Coronavirus: guidelines for managing diabetes during an illness. https://www.idf.org/aboutdiabetes/what-is-diabetes/covid-19-and- diabetes.html

8. He H.-wu, Liu D.-wei, Long Y. Wang X.-ting (2016) High central venous-to-arterial CO2 difference/arterial-central venous O2 difference ratio is associated with poor lactate clearance in septic patients after resuscitation. Critical Care, vol. 31 pp. 76–81.

9. Wittayachamnankul B., Chentanakij B., Sruamsiri K., Chattipakorn N (2016) The role of central venous oxygen saturation, blood lactate, and central venous-to-arterial carbon dioxide partial pressure difference as a goal and prognosis of sepsis treatment. Crit Care, vol. 36, pp. 223–229. doi: 10.1016/j.jcrc.2016.08.002.

10. Sivitz W.I. Phillip L.S., Wexler D.J., Fortmann S.P., Camp A.W., Tiktin M. and the GRADE Research Group (2020) Optimization of metformin in the GRADE cohort: effect on glycemia and body weight. Diabetes Care, vol. 43, no 5, pp. 940–947. doi.org/10.2337/dc19-1769

11. Isachkina O.N. Danilova L.I. (2018) Disglikemiya kriticheskikh sostoyaniy [Critical Dysglycemia] Neotlozhnaya kardiologiya i kardiovaskulyarnyye riski, no 2, pp. 302-312.

12. Gunst, J. Bruyn A, Van den Berghe G. (2019) Glucose control in the ICU. Opin Anaesthesiol, vol. 32, no 2, pp. 156–162. doi: 10.1097/ ACO.0000000000000706. PMID: 30817388

13. Clodi ,M. Resl M., Abrahamian H., Föger B., Weitgasser R. Wien (2019) Treatment of hyperglycemia in adult, critically ill patients (Update 2019) Klin Wochenschr, vol. 131, no 1, pp. 218–220. doi: 10.1007/s00508-019-1486-5. PMID: 30980173 Review.

14. Isachkina O.N. Danilova L.I. (2018) Kontrol’ parametrov glikemii u patsiyentov v kriticheskom sostoyanii [Glycemic control parameters in patients in critical condition]. Laboratornaya diagnostika. Vostochnaya Yevropa, no 2, pp. 258–268.

15. Sheng Ch.-Sh. Tian J., Miao Y., Cheng Y., Yang Y., Reaven P. D., Bloomgarden Z.T., Ning G. (2020) Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. Diabetes Care, vol. 43, no 6, pp. 1185–1190. doi.org/10.2337/dc19-2589

16. García-Gallegos D.J., Luis-López E. (2017) Prediabetes as a riskmarker for stress-induced hyperglycemia in critically ill adults. Rev Med Inst Mex Seguro Soc, vol. 55, no 1, pp. 14–S19. PMID: 28212470

17. Yamada, T. Shojima N, Noma H, Yamauchi T, Kadowaki T. (2017) Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Med, vol. 43, no 1, pp. 1–15. doi: 10.1007/s00134-016-4523-0.

18. Hersh A.M., Hirshberg E.L., Wilson E.L. (2018) Lower glucose target is associated with improved 30-day mortality in cardiac and cardiothoracic patients. Chest, pii: S0012-3692(18)30646-9. doi: 10.1016/j.chest.2018.04.025.

19. Le P., Chaitoff A., Misra-Hebert A. D., Ye W., Herman W. H., Rothberg M. B. (2020) Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey. Diabetes Care, vol. 43, no 6, pp. 1227–1233.

20. Tran K.K., Kibert J.L. 2nd, Telford E.D., Franck A.J. (2019) Intravenous insulin infusion protocol compared with subcutaneous insulin for the management of hyperglycemia in critically ill adults. Ann Pharmacother, vol. 53, no 9, pp. 894–898. doi: 10.1177/1060028019841363.

21. Gracia-Ramos, A.E. (2020) Is the ACE2 overexpression a risk factor for COVID-19 infection? Archives of Medical Research. https://doi.org/10.1016/j. arcmed.2020.03.011

22. Ceriello A. Stoian A.P., Rizzo M. (2020) COVID-19 and diabetes management: what should be considered? Diabetes Research and Clinical Practice. doi.org/10.1016/j.diabres. 2020.108151

23. Wan Y., Shang J. Graham R., Baric R.S, Li F. (2020) Receptor Recognition by the Novel Coronavirus From Wuhan: An Analysis Based on Decade- Long Structural Studies of SARS Coronavirus. Virol, vol. 94, no 7, pp. e00127–20. doi: 10.1128/JVI.00127-20.

24. Khan A., Benthin C., Zeno B., Albertson T.E., Boyd J., Christie J.D., Hall R., Poirier G, Ronco J.J., Tidswell M., Hardes K., Powley W.M., Wright T.J., Siederer S.K., Fairman D.A., Lipson D.A., Bayliffe A.I., Lazaar A.L. (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Car, vol. 21, no 1, pp. 234. doi: 10.1186/s13054-017-1823-x.

25. Kim W.Y., Jo E.J., Eom J.S., Mok J., Kim M.H., Kim K.U., Park H.K., Lee M.K., Lee K. (2018) Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: propensity score-based analysis of a before-after cohort study. Crit Care, vol. 47, pp. 211–218.

26. Carr A.C. (2020) A new clinical trial to test high-dose vitamin C in patients with COVID-19. Critical Care, vol. 24, no 133. doi.org/10.1186/s13054- 020-02851-4

27. Berg K.M. Gautam S., Salciccioli J.D., Giberson T., Saindon B., Donnino M.W. (2014) Intravenous thiamine is associated with increased oxygen consumption in critically ill patients with preserved cardiac index. Ann Am Thorac Soc, vol. 11, no 10, pp. 1597–1601.

28. Greiller, C.L.; Martineau, A.R. (2015) Modulation of the immune response to respiratory viruses by vitamin D. Nutrients, vol. 7, pp. 4240–4270.

29. Wang D. Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, vol. 323, no 11, pp. 1061–1069.

30. Pludovski P., Holic M.F., Grant W.B. (2018) Vitamin D Supplementation Guidelines Practice Guideline. J Steroid Biochem Mol Biol; vol. 175, pp. 125–135. doi: 10.1016/j.jsbmb.2017.01.021.

31. Lushchyk M., Sivuda V., Tuzava H., Drozd V. 25-hydroxyvitamine D status and vitamin D receptor gene polymorphism in thyroid nodular disease patients. Proceedings of the 86th ATA Annual meeting, (Denver, Colorado, USA October, 2016), pp. 245.

32. Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L., Bhattoa H.P. (2020) Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, vol. 12, pp. 988. doi:10.3390/nu12040988

33. Wimalawansa S.J. (2020) Global epidemic of coronavirus–COVID-19: What we can do to minimze risks. Eur. J. Biomed. Pharm. Sc., vol. 7, pp. 432–438.

34. Hussain A., Bhowmik B., do Vale Moreira (2020) COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract, vol. 162, pp. 108–142. doi: 10.1016/j.diabres.2020.108142. Epub 2020 Apr

35. Bhadada S.K. (2020) Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. doi.org/10.1016/j. diabres.2020.108146


Для цитирования:


Данилова Л.И., Лущик М.Л., Исачкина О.Н., Валуевич В.В. Сахарный диабет, дисгликемия и COVID-19: новое в коррекции и профилактике осложнений. Рецепт. 2020;(2-3):362-369. https://doi.org/10.34883/PI.2020.2.2.042

For citation:


Danilova .L., Lushchyk .M., Isachkina .O., Valuуevich .V. Diabetes Mellitus, Dysglycemia, and COVID-19: New in the Correction and Prevention of Complications. Recipe. 2020;(2-3):362-369. (In Russ.) https://doi.org/10.34883/PI.2020.2.2.042

Просмотров: 18


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)